Apigenin appears in weight loss content on the strength of two mechanisms: it inhibits fat cell formation, and it turns white fat brown. Both mechanisms are real findings from real studies. The problem is that a 2025 experiment fed oral apigenin to middle-aged rats for 88 days and found neither of them happened.
Key Takeaways
- A 2020 study found apigenin reduced body weight and visceral fat in obese mice, but specifically did not reduce subcutaneous or epididymal fat.
- That same 2020 paper carries a published erratum, which is worth knowing before citing its numbers.
- The white to brown fat conversion result came from cultured cells and cocultures, not from a live animal losing weight.
- A 2025 study gave oral apigenin to middle-aged rats for 88 days. It failed to prevent obesity and did not affect adipose browning genes, sirtuins or CD38.
- That same 2025 study did find a real effect: it reduced obesity-related muscle loss through p70S6K signaling. The benefit was in muscle, not fat.
The Visceral Fat Study, and Its Own Limits
The most cited paper here appeared in Pharmacological Research in 2020.[1] Researchers screened dietary compounds for anti-visceral-obesity activity and found apigenin significantly reduced body weight and visceral adipose tissue in high fat diet mice.
The mechanism is specific. In visceral obesity, STAT3 in adipocytes is constitutively active. The authors showed the high fat diet increased STAT3 phosphorylation in visceral fat, that apigenin binds non-phosphorylated STAT3 and reduces its phosphorylation and transcriptional activity, and that this lowers expression of CD36 and then PPAR gamma, the critical nuclear factor in fat cell formation. They confirmed the causal chain by overexpressing constitutively active STAT3, which reversed the effect.
Now the part that summaries drop. The study reported reduced visceral adipose tissue but explicitly not subcutaneous or epididymal adipose tissue. The authors also showed the high fat diet raised STAT3 phosphorylation in visceral fat but not in those other depots, which explains why. This is a depot-specific finding, not general fat loss.
One housekeeping note. This paper has a published erratum in Pharmacological Research in 2023. An erratum does not mean a study is wrong, and errata range from an author affiliation to a corrected figure. It does mean anyone quoting exact numbers from it should check which values the correction touched.
The Browning Result Came From a Dish
The white to brown fat conversion claim traces to a 2022 study in Journal of Cellular Biochemistry.[2] Researchers looked at whether modulating blood vessel growth in fat tissue changes its metabolism, selected apigenin as a proangiogenic compound, and found it enhanced both new differentiation and transdifferentiation of mouse white adipocytes toward a brown-like phenotype.
Coculture experiments with endothelial cells showed the browning ran through vascular endothelial growth factor A and upregulation of the PRDM16 cascade. PRDM16 is the recognized master regulator of brown fat identity, so the mechanism is plausible rather than hand-waved.
What this study did not do is put apigenin into an animal and observe a metabolic shift or weight change. It was cell and coculture work proposing a new insight for inducing a metabolic shift. That is how the authors framed it.
The 2025 Study That Tested the Whole Story Orally
A 2025 paper in Biomedicine and Pharmacotherapy is the most informative result in this topic, and it is the one weight loss content does not mention.[3]
Forty-seven 15-month-old male Wistar rats were assigned to standard diet or high calorie diet, each with or without oral apigenin at 50 mg per kilogram, plus a vehicle control. Obesity induction and treatment ran concurrently for 88 days. This is a preemptive design in middle-aged animals, which is closer to how a person takes a longevity supplement than a young-mouse short-course study is.
The diet worked. After 88 days the high calorie diet rats had hyperglycemia, hypertriglyceridemia, increased visceral and subcutaneous fat, and cardiac hypertrophy. Apigenin did not prevent any of it. The authors state it failed to prevent obesity, and specifically that it did not affect key adipose tissue browning genes, cardiac oxidative stress markers, or sirtuin and CD38 levels.
Read the middle clause again, because it tests two separate popular claims at once. The browning genes did not move. The sirtuin and CD38 levels did not move, and CD38 inhibition is the mechanism behind apigenin’s NAD and longevity framing elsewhere on this site. In this model, given orally for nearly three months, neither mechanism registered.
What That Study Did Find
The 2025 paper was not a null result overall. The gastrocnemius muscle of the obese rats showed reduced mass, smaller myocytes and fibrosis, indicating sarcopenia worsened by obesity. Apigenin mitigated that muscle loss and hypotrophy, and raised p70S6K, an anabolic signaling protein.
So the honest summary of the best oral, long-duration, aging-model evidence is close to the inverse of the marketing: apigenin did not stop the fat accumulating, and did help preserve the muscle that obesity was eroding. The authors themselves point toward sarcopenia subtypes rather than obesity as the direction worth pursuing.
The Blood Pressure Study, and Why It Is Not Quite the Same Claim
A 2024 study in Biochimica et Biophysica Acta examined dietary apigenin in obesity-related hypertension.[4] Apigenin improved vasodilation and reduced blood pressure in obese mice, partly through endothelial TRPV4 channels, since the effect was partly blocked in TRPV4 knockout animals. It also increased adiponectin secretion from brown fat by downregulating CD38 and restoring NAD and SIRT1 signaling.
This paper does report reduced weight gain, independent of TRPV4. It is a point in favor of a metabolic effect, and it is a mouse study running the opposite conclusion on CD38 to the 2025 rat study. Holding both is the accurate position: species, age, duration and diet all differ, and the literature has not resolved it.
The primary endpoint here was blood pressure, not body composition, which is a separate topic from whether apigenin reduces fat. A review of chamomile in obesity and metabolic syndrome reached a similarly unsettled conclusion, describing the potential as underestimated while noting the evidence sits in cell and animal models.[5]
A related distinction is worth drawing here, because the two questions get merged. A 2024 study found apigenin ameliorates obesity-induced insulin resistance in the liver by targeting fetuin-A, a hepatokine that binds insulin receptors and blocks insulin signaling.[6] Apigenin reduced fetuin-A expression and promoted its degradation, restoring insulin receptor substrate 1 and Akt phosphorylation in cells and in high fat diet mice. That is a finding about insulin sensitivity, not about fat mass. Improving how an obese animal handles glucose is not the same claim as making it less obese, and this article is about the second one.
Doses, and What They Convert To
The 2025 rat study used 50 mg per kilogram. Rats scale to humans by roughly a factor of six on the standard body surface area method, giving a human equivalent near 8 mg per kilogram, or about 560 mg for a 70 kg adult. That is roughly eleven to twenty-two typical capsules per day, taken for 88 consecutive days, to produce the result described above, which was no effect on obesity.
This is the arithmetic that decides the topic. A dose an order of magnitude above normal supplementation, given preemptively for nearly three months, did not prevent diet-induced fat gain in the animal model. Nothing about a 25 mg or 50 mg capsule improves on that.
Bottom Line
The mechanisms are real and the popular summary of them is not. Apigenin inhibits adipocyte differentiation through the STAT3 to CD36 to PPAR gamma axis, and reduced visceral fat specifically, while leaving subcutaneous and epididymal fat unchanged, in obese mice. It pushed cultured white adipocytes toward a brown phenotype through VEGF and PRDM16, in a dish. Then a 2025 study gave it orally at 50 mg per kilogram to middle-aged rats for 88 days and found no prevention of obesity and no movement in browning genes, sirtuins or CD38, while finding a genuine benefit in preserving muscle. No human trial has tested apigenin for weight or body composition. Anyone considering it for fat loss is buying the cell study and ignoring the animal study.
Frequently Asked Questions
Does apigenin help you lose weight?
No human trial has tested apigenin for weight or body composition. In obese mice a 2020 study found it reduced body weight and visceral fat specifically, while leaving subcutaneous and epididymal fat unchanged. A 2025 study gave oral apigenin at 50 mg per kilogram to middle-aged rats for 88 days and reported it failed to prevent obesity.
Does apigenin turn white fat into brown fat?
In cell culture and coculture, apigenin drove mouse white adipocytes toward a brown-like phenotype through VEGF and the PRDM16 cascade. That result came from a dish rather than a live animal. A 2025 study measuring adipose browning genes in rats given oral apigenin for 88 days found the browning genes were not affected.
How much apigenin did the fat studies use?
The 2025 rat study used 50 mg per kilogram daily for 88 days. Converting by the standard body surface area method, rats scale down by roughly a factor of six, putting the human equivalent near 8 mg per kilogram or about 560 mg for a 70 kg adult. That is many times a typical 25 mg or 50 mg capsule, and at that dose the study still found no prevention of obesity.
References
- Su T, Huang C, Yang C, et al. Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity. Pharmacological Research (2020). PMID 31877350
- Sreekumar S, Vijayan V, Singh F, et al. White to brown adipocyte transition mediated by apigenin via VEGF-PRDM16 signaling. Journal of Cellular Biochemistry (2022). PMID 35926149
- de Castro JM, da Silva Melo A, Silveira BL, et al. Oral apigenin prevents obesity-related muscular atrophy, but not obesity itself, in middle-aged rats fed a high-calorie diet. Biomedicine and Pharmacotherapy (2025). PMID 40652723
- Mou A, Sun F, Tong D, et al. Dietary apigenin ameliorates obesity-related hypertension through TRPV4-dependent vasorelaxation and TRPV4-independent adiponectin secretion. Biochimica et Biophysica Acta Molecular Basis of Disease (2024). PMID 39218272
- Bayliak MM, Dmytriv TR, Melnychuk AV, et al. Chamomile as a potential remedy for obesity and metabolic syndrome. EXCLI Journal (2021). PMID 34602925
- Hsu MC, Chen CH, Wang MC, et al. Apigenin targets fetuin-A to ameliorate obesity-induced insulin resistance. International Journal of Biological Sciences (2024). PMID 38481798
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
